Enzolytics Inc (ENZC)

[falon]

Enzolytics, Inc. (ENZC) is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Enzolytics is committed to creating drugs for the better health of mankind.

Where did ENZC come from:
PLANO, TX / ACCESSWIRE / September 16, 2020 / Enzolytics, Inc. (OTC PINK:ENZC or the "Company") today announced the execution of a non-binding letter of intent (the "LOI") to merge with BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics") a biotech company located in Dallas Texas.

About Enzolytics, Inc;
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind.
Enzolytics' flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.

About BioClonetics Immunotherapeutics, Inc.
BioClonetics Immunotherapeutics, Inc. is a Dallas Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for produce fully human monoclonal antibodies may be use to produce therapeutics treatments for name infectious diseases including the Coronavirus.

What are they doing?
On September 15, 2020, Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics") entered into a non-binding letter of intent to combine the two entities and pursue our joint mission to create therapeutics that are effective and affordable for the treatment of some of the most infectious and deadly diseases in the world, including HIV and the Coronavirus. This goal has as its foundation several components - (1) our patented anti-HIV therapeutics that have been successfully clinically tested, (2) our anti-HIV monoclonal parent antibody previously tested in vitro, demonstrating neutralization of over 95% of the HIV isolates against which it was tested and (3) our proprietary methodology for producing fully human monoclonal antibodies which is being used to produce additional anti-HIV monoclonal antibodies targeting additional immutable sites on the HIV virus as well as multiple anti-CoronaVirus monoclonal antibodies for use as a therapeutic against the SARS-CoV-2 virus.

On December 1, 2020, the combination agreement was completed, and the control block of shares of Enzolytics was transferred in accordance with the terms of the final document to Dr. Joseph Cotropia, Dr. Gaurav Chandra, and me, officially integrating the management teams and organizations into one single-purposed organization.

Enzolytics Inc. brings to the table ITV-1 and BioClonetics Immunotherapeutics, Inc. brings fully human monoclonal antibodies (mAbs).

"The combination of our two companies' proprietary technologies and products is a once in a lifetime opportunity that should benefit both of our organizations letting us achieve more together than we could apart", stated Harry Zhabilov, CEO of ENZC.

The therapies of Enzolytics' two technologies, that produced by Enzolytics and that created by BioClonetics will be tested in combination and are expected to be synergistic.

Is it cost effective?
"The current antiretroviral therapy for HIV/AIDS is not a cure, and the side effects from lifelong use are significant. Also, the yearly average cost of treatment on anti-retroviral is $14,000 to $20,000 per year, and the average lifetime cost is calculated as $379,000. The cost of an anti-HIV therapy we propose would be a fraction of these costs as the treatment would be for a limited time and not require life-long use.

What has ENZC accomplished since the merger process began (September 15, 2020-December 30, 2020)?
1. Enzolytics, Inc. Files Provisional Patent for Treatment of Multiple Sclerosis
2. Enzolytics, Inc. Engages BTS Research to Conduct Toxicity Study
3. Opened Laboratory on the campus of Texas A&M University in the University's Institute for Preclinical Studies.
4. Successfully raised necessary funding to execute our plans. Our initial $500,000 raise is being followed with $1 million being funded in the next 30 days, and additional investment is being made into the Company by officers of the Company, bringing the total raised since the signing of the non-binding letter of intent to $1.7 million.
5. The Company has also negotiated a debt exchange whereby most of the existing convertible debt has been exchanged for equity instruments that have a two-year conversion clause to postpone conversions for the next two years.
6. We have engaged an artificial intelligence (AI) and genetics and molecular biology data science team to curate the thousands of isolates (strains) now known as existing in both the HIV virus and the SARS-CoV-2 virus. This process will allow us to identify conserved, immutable targets against which monoclonal antibodies are to be produced.
7. Testing of the newly produced monoclonal antibodies is also being arranged. This includes testing of our now being produced recombinant anti-HIV monoclonal antibodies created from the parent antibody. Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France.
8. Since the signing of the original non-binding letter of intent, the Company has filed two annual reports and eight quarterly reports, with the required OTC alternative reporting supplemental information, and will soon be filing the last quarterly filing and opinion letter with OTC Markets needed to bring the Company to a current status.
9. By combining our expertise with outside professionals and trusted consultants, we have succeeded in less than three months in accomplishing each of these items - as well as others.
Sometimes things aren't clear right away. That's where you need to be patient and persevere and see where things lead.
Mary Pierce
What has ENZC accomplished since January 1, 2021 to present day)?

1. 02/07/2021 Annual Report - Corrected Annual Report 12-31-2020
2. 01/11/2021 Attorney Letter with Respect to Current Information - Attorney Letter for 12-31-2019, 2018 and related Qtrs 3-31-2020, 6-30-2020 and 9-30-2020
3. 01/11/2021 Quarterly Report - For the period ended September 30, 2020 Disclosure Information
4. 01/11/2021 Quarterly Report - For the period ended June 30, 2020 Disclosure Information
5. 01/11/2021 Quarterly Report - For the period ended March 31, 2020 Disclosure Information
6. 01/11/2021 Annual Report - Annual Report Disclosure information December 31, 2019
7. 01/11/2021 Annual Report - Annual Report for the Year Ended December 31, 2019
8. 01/11/2021 Annual Report - Annual Report Disclosure Information Corrected 12-31-2018
9. 01/07/2021 Quarterly Report - For the period ended June 30, 2020 06/30/2020
10. 01/06/2021 Quarterly Report - For the period ending 9-30-2020
11. Enzolytics, Inc. Engages PCAOB Auditor for December 31, 2020 Year End Audit.
12. Enzolytics, Inc. Receives Official Filing Receipt for Multiple Sclerosis Patent Application.
13. Enzolytics Announces The Discovery Of Seven Newly Identified Conserved Target Sites On The HIV Virus.
14. Enzolytics Inc. Reports Test Results of its Patented ITV-1 Conducted at the National Centre of Infectious and Parasitic Diseases. COLLEGE STATION, TX / ACCESSWIRE / February 16, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") announced today the results of an in vitro study of the Company's ITV-1/IPF peptide treatment that demonstrated the broad efficacy with low toxicity. The Company's ITV-1 peptide was tested against human corona virus 229E Strain (HCoV-229E) and exhibited comparable efficacy but with a 20-fold lower toxicity than the widely used anti-influenza medicine Tamiflu®.
15. Enzolytics Updates Permitting Progress in Europe on Its Planned Clinical Trials of Its Patented ITV-1 Anti-HIV and Other Developments.
16. Enzolytics Announces the Discovery and Patenting of Eleven Newly Identified Conserved Target Sites on the SARS-CoV-2 Virus (Coronavirus).
17. Enzolytics Announces the Discovery and Patenting of 8 Newly Identified Conserved Target Sites on the HIV-1 Virus.
18. COLLEGE STATION, TX / ACCESSWIRE / March 16, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced the formalization of corporate legal documents pursuant to Articles of Association forming International Medical Partners ("IMPL") a Bulgarian Limited Liability Company of which the Company is 50% owner. The agreements are with the Company's partners in IMBL formed with a group of successful Bulgarian businessmen.
As a team, the Company with IMPL is moving forward to complete the initial production and certification of its ITV-1 patented therapeutics for treating HIV leading to the planned clinical trials under the European Medicine Agency (the "EMA"). A commitment for funding of the cost of clinical trials under EMA guidelines and cost associated with the issuance of an EMA permit are part of the negotiated agreements. Under the Mutual Recognition Agreement (the "MRA") between the EMA and the United States Federal Drug Administration (the "FDA"), the Company's belief is that issuance of the EMA permit for the ITV-1 compound should qualify ENZC's treatment for recognition by the FDA.

Patience is not simply the ability to wait - it's how we behave while we're waiting.

Joyce Meyer

What do we know as shareholders?
We know what the company has told us and information we find through research and COMMON SENSE.
Some FACTS we KNOW:
1. AI has been a factor

2. Monoclonal Antibodies being produced

3. Toxicity study results imminent

4. 19+ Patents

5. 2020 Annual Report imminent

6. PCOAB for 2019 and 2020 expected next month

7. The application for OTCQB is being prepared for submission upon issuance of the Audited Statements

8. Charles is in Charge

What we don't know:

1. Relationship to Gilead?

2. Relationship to Eli Lily?

3. Relationship to Immunome?

4. Acquisition?


So what does all of this mean?
ENZC is not a scam as some people all over the internet would have you to believe. It needs money as any company would to run its operations. It has been successful thus far keeping the lights on. They will continue to need funding moving forward so that is something to watch for.
Why is so special about ENZC?
TWO things NO VIRUS ESCAPE and LOW TOXICITY.
The problem with many viruses is that they mutate. Many treatments for virus allows for mutations and may be toxic to other body functions.

Here is why ENZC are confident in their technology:
It will be imperative that produced antibodies target a conserved and immutable site on the virus - otherwise the antibody (over time) will be rendered ineffective due to mutation - known as “virus escape”. Our anti-HIV monoclonal antibody targets an immutable virus site on the HIV virus - one that is constant within virtually all 6000 now known different HIV isolates (strains) of the virus. The CoronaVirus has structure correlative to that of the HIV virus. Because our primary anti-HIV monoclonal antibody has been proven to neutralize numerous different strains of the HIV virus in tests in 5 international labs, and knowing the binding site on the HIV virus to which our antibody binds resulting in neutralization, this knowledge provides insight necessary to identifying corresponding structure (amino acid sequences) on the CoronaVirus that should be targeted to effectively neutralize the CoronaVirus. Moreover, we have proprietary methodology needed to produce anti-CoronaVirus monoclonal antibodies targeting such known - to us - sites.
The Company has also pioneered a proprietary method for creating human cell lines that produce fully human monoclonal antibodies directed against many infectious diseases.
These HIV therapeutics may be used as an immunotherapeutic treatment for individuals with HIV/AIDS. They may also be developed for use as a prophylactic and therapeutic vaccine to prevent uninfected populations from contracting the HIV virus. Treatment using the fully human anti-HIV antibody will be far superior to current ARV therapy for several significant reasons: (1) the therapy will be effective and non-toxic, (2) will not require lifetime treatment and (3) will be far less expensive.
Thus, for the patient, immunotherapy will be remarkably different — it will be safer, provide a much-needed immunotherapeutic cure rather than requiring lifelong treatment and costs substantially less than current antiretroviral therapy.
The Company also has created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus and diphtheria. As a part of its mission, the Company is testing these antibodies to prepare them for use as therapies against these diseases.

In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation

ENZC is by no means a slam dunk however their technology is certainly different from other company’s technology that is on the market. There is still much work to be done as evident with the last press release. It is a LONG ROAD in the field of Biotechnology as nothing happens overnight however as companies make progress in their endeavors, the results sometimes can be earth-shattering.

The QUESTION is will ENZC have some EARTH-SHATTERING moments?

I BELIEVE SO

EZNZC checks many of the boxes of a good biotechnology to invest in. Good management, hot sector, collaborative support, product pipeline with potential are some of the boxes checked off. Another BIG plus for ENZC technology is that it will be at a reasonable price unlike many other drugs that come to the market that are cost prohibitive.

INSURANCE COMPANIES are going to LOVE ENZC while the COMPETITION are going to HATE us.

My biggest weakness is patience, wanting to see things happen too quickly or get changes in place right away. Not having the patience to let things develop.

Paul Gleason

ENZC Website:
https://enzolytics.com/

The link below has all ENZC Press Releases:
https://marketwirenews.com/stock/enzc/news/